Skip to main content
Premium Trial:

Request an Annual Quote

Emerald BioStructures, UCB Expand Drug Discovery Collaboration

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Emerald BioStructures and UCB today said that they have a achieved a second milestone in their ongoing collaboration and have expanded the alliance.

Bainbridge Island, Wash.-based Emerald said that it and UCB researchers have solved high-resolution X-ray crystallographic structures of multiple targets and have identified a unique lead series of small molecules. The firm said that it achieved that milestone within two years, since the firms initiated their collaboration in January 2009.

Emerald also said that the firms have decided to expand the agreement, though it provided few details. The expansion will result in undisclosed research fees, a milestone payment, and royalties. Emerald said that the financial terms would support multiple full-time researcher equivalents at the firm.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more